<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320774</url>
  </required_header>
  <id_info>
    <org_study_id>Treatment with Daivobet® Gel</org_study_id>
    <nct_id>NCT01320774</nct_id>
  </id_info>
  <brief_title>Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris</brief_title>
  <official_title>Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma GmbH, Neu-Isenburg, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to evaluate the efficacy, tolerability, quality of
      life and handling of Daivobet® Gel by both physician and patient in daily practise.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Handling of Daivobet® Gel</measure>
    <time_frame>After appr 4 weeks</time_frame>
    <description>Compared to previous topical treatment: Time required for application (previous treatment versus present treatment), time required until dressing is possible (previous treatment versus present treatment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4 weeks</time_frame>
    <description>Dermatology Life Quality Index (DLQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global Assessment of psoriasis vulgaris</measure>
    <time_frame>4 weeks</time_frame>
    <description>6-step scale from &quot;no visible disease (O)&quot; to &quot;very severe disease (5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>4 weeks</time_frame>
    <description>number of participants with serious and non-serious adverse drug reactions, according to organ classes</description>
  </secondary_outcome>
  <enrollment type="Actual">588</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivobet® Gel</intervention_name>
    <description>Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients visiting their attending dermatologist in the primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with light to moderate psoriasis vulgaris of trunk and extremities and
             treatment with Daivobet® Gel was planned anyway

        Exclusion Criteria:

          -  Previous therapy with Daivobet® Gel

          -  Systemic therapy of psoriasis vulgaris

          -  Contraindications of Daivobet® Gel in the German package insert
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Sticherling, Prof dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University clinic Erlangen-Nuernberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Clinic of Erlangen Nuernberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>February 9, 2012</last_update_submitted>
  <last_update_submitted_qc>February 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

